Table 4 Prognostic impact of CDX2 expression and CRC subtypes, tumour budding and WHO grade in microsatellite subgroups of UICC Stage II/III CRCs.
UICC Stage II/III CRCs | Overall, n (%) | Mean overall survival (SE) | P value | Mean disease-specific survival (SE) | P value | Mean disease-free survival (SE) | P value | |
|---|---|---|---|---|---|---|---|---|
Microsatellite status: MSS subcohort | 0.261 | 0.05 | 0.009 | |||||
CDX2 expression | CDX2-low/absent | 39 (7.4%) | 100.53 (14.18) | 108.11 (14.60) | 96.84 (14.81) | |||
CDX2-high | 486 (92.6%) | 133.55 (5.57) | 160.71 (5.29) | 154.04 (5.31) | ||||
Microsatellite status: MSI-high subcohort | 0.069 | 0.170 | 0.125 | |||||
CDX2 expression | CDX2-low/absent | 39 (32.8%) | 114.33 (16.65) | 157.33 (15.27) | 148.10 (16.49) | |||
CDX2-high | 80 (67.2%) | 140.79 (9.64) | 164.17 (8.40) | 162.96 (8.37) | ||||
Microsatellite status: MSS subcohort | <0.001 | <0.001 | <0.001 | |||||
Tumour budding activity | Bd1 | 265 (50.5%) | 158.75 (6.60) | 186.29 (5.56) | 188.17 (4.99) | |||
Bd2 | 160 (30.5%) | 116.22 (8.96) | 139.12 (9.16) | 118.43 (9.27) | ||||
Bd3 | 100 (19%) | 69.90 (7.50) | 81.04 (8.54) | 70.02 (8.45) | ||||
Microsatellite status: MSI-high subcohort | <0.001 | <0.001 | <0.001 | |||||
Tumour budding activity | Bd1 | 82 (68.9%) | 153.20 (8.95) | 182.55 (5.89) | 177.94 (6.53) | |||
Bd2 | 24 (20.2%) | 110.77 (19.17) | 146.80 (20.32) | 148.86 (19.84) | ||||
Bd3 | 13 (10.9%) | 38.85 (12.53) | 32.52 (10.35) | 26.74 (10.12) | ||||
Microsatellite status: MSS subcohort | 0.021 | 0.001 | <0.001 | |||||
WHO grade | Low grade | 384 (73.1%) | 132.22 (5.85) | 160.30 (5.54) | 154.36 (5.36) | |||
High grade | 141 (26.9%) | 119.27 (9.16) | 133.62 (9.48) | 122.37 (9.77) | ||||
Microsatellite status: MSI-high subcohort | 0.124 | 0.271 | 0.283 | |||||
WHO grade | Low grade | 55 (46.2%) | 153.56 (14.02) | 175.68 (12.27) | 176.71 (10.49) | |||
High grade | 64 (53.8%) | 120.86 (10.93) | 152.77 (10.20) | 148.68 (10.62) | ||||
Microsatellite status: MSS subcohort | 0.023 | <0.001 | <0.001 | |||||
CRC subtypes | Adenocarcinoma NOS | 355 (67.6%) | 138.24 (6.45) | 164.18 (6.08) | 161.02 (5.94) | |||
Mucinous adenocarcinoma | 36 (6.8%) | 107.63 (13.25) | 130.72 (13.39) | 121.12 (14.16) | ||||
Signet-ring cell carcinoma | 5 (0.9%) | 21.09 (8.17) | 21.09 (8.17) | 16.37 (7.42) | ||||
Medullary adenocarcinoma | 4 (0.8%) | 128.47 (22.01) | 128.47 (22.01) | 128.47 (22.01) | ||||
Micropapillary adenocarcinoma | 69 (13.1%) | 109.10 (13.00) | 122.12 (13.54) | 102.33 (13.50) | ||||
Serrated adenocarcinoma | 47 (8.9%) | 96.96 (11.43) | 115.32 (11.76) | 100.91 (11.57) | ||||
Adenoma-like adenocarcinoma | 8 (1.5%) | 133.30 (23.63) | 133.30 (16.71) | 133.30 (16.71) | ||||
MANEC/NEC | 1 (0.2%) | 21.67 (0.00) | 21.67 (0.00) | 10.00 (0.00) | ||||
Microsatellite status: MSI-high subcohort | 0.131 | 0.002 | 0.010 | |||||
CRC subtypes | Adenocarcinoma NOS | 47 (39.5%) | 142.68 (14.62) | 169.78 (13.12) | 172.86 (11.70) | |||
Mucinous adenocarcinoma | 23 (19.3%) | 107.05 (15.77) | 127.18 (15.82) | 119.86 (16.63) | ||||
Signet-ring cell carcinoma | 2 (1.7%) | 16.77 (0.00) | 15.77 (0.00) | 12.00 (0.00) | ||||
Medullary adenocarcinoma | 28 (23.5%) | 142.62 (14.86) | 187.09 (7.40) | 179.72 (10.08) | ||||
Micropapillary adenocarcinoma | 5 (4.2%) | 38.56 (14.61) | 38.56 (14.61) | 35.22 (16.06) | ||||
Serrated adenocarcinoma | 9 (7.6%) | 148.35 (19.38) | 150.43 (17.01) | 146.09 (21.28) | ||||
Adenoma-like adenocarcinoma | 2 (1.6%) | 70.37 (0.00) | 70.37 (0.00) | 70.37 (0.00) | ||||
MANEC/NEC | 3 (2.5%) | 38.46 (14.51) | 38.46 (14.51) | 38.46 (14.51) |
